Today's Daily Dose brings you news about SCYNEXIS' Dove study results; termination of the merger agreement between Idera and BioCryst Pharma; withdrawal of Advaxis' Conditional Marketing Authorization Application in the European Union for Axalimogene filolisbac and stock offering of ArQule.
from RTT - Biotech https://ift.tt/2um4w1a
via IFTTT
No comments:
Post a Comment